Consistent with the strategy developed with the modeled kinetics of the serum tumor marker CA-125 in ovarian cancer patients treated with chemotherapy, producing a strong and reliable prognostic marker of OS called KELIM (CA-125 ELIMination constant rate K) [20,21,22], we proposed to assess the prognostic value of PSA kinetics in this trial as a way of identifying some patients who might have benefited from adding docetaxel to ADT. This evidence concerns the gene KLK3 and ovarian carcinoma.